Silexion Therapeutics Ltd... (SLXN)
NASDAQ: SLXN
· Real-Time Price · USD
7.39
0.03 (0.41%)
At close: Aug 15, 2025, 3:56 PM
7.24
-2.03%
After-hours: Aug 15, 2025, 07:47 PM EDT
Silexion Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -1.65M | -1.9M | -8.04M | -1.39M | -1.25M | -1.73M | -731K | -155.47K | -808 | -488.11K | -237K | -156.99K | -350.24K | -433.4K | n/a | -195.06K | -92.65K |
Interest Income | n/a | n/a | n/a | 6K | 19K | 33K | 227.05K | 318K | 745.04K | 992.92K | 520.02K | 163.34K | 9.39K | 2.18K | 1.77K | 1.75K | 676.00 |
Pretax Income | -1.74M | -1.75M | -11.86M | -1.49M | -1.42M | -1.67M | -803K | 162.95K | -733 | 494.41K | 292.58K | 42.69K | -245.66K | -241.77K | -224K | -191.79K | -97.75K |
Net Income | -1.74M | -1.75M | -11.86M | -1.47M | -1.42M | -1.73M | 787.00 | 162.95K | -774 | 494.41K | 292.58K | 42.69K | -246K | -242K | -224K | -192K | -97.75K |
Selling & General & Admin | 1.06M | 1.04M | 4.82M | 619K | 281K | 465K | 186K | 155.47K | 127.00 | 488.11K | 237K | 156.99K | 350.24K | 433.4K | n/a | 195.06K | 92.65K |
Research & Development | 590K | 871K | 3.22M | 766K | 961K | 1.26M | 535K | n/a | 681.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | -12K | n/a | n/a | 8K | 6K | 10K | 2.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.65M | 1.9M | 8.04M | 1.39M | 1.25M | 1.73M | 731K | 2.22M | 808.00 | 488.11K | 237K | 156.99K | 350.24K | 433.4K | n/a | 195.06K | 92.65K |
Interest Expense | 9K | n/a | n/a | 2K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.65M | 1.9M | 8.04M | 1.39M | 1.25M | 1.73M | 731K | 155.47K | 808.00 | 488.11K | 237K | 156.99K | 350.24K | 433.4K | n/a | 195.06K | 92.65K |
Income Tax Expense | n/a | 1K | 2K | 2K | 5K | 6K | 6K | n/a | 10.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.78M | 9.24M | 6.48M | 4.3M | 1.12M | 971.2K | 5.53M | 6.61M | 12.06M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M |
Shares Outstanding (Diluted) | 6.78M | 9.24M | 6.48M | 4.3M | 1.12M | 971.2K | 5.53M | 6.61M | 12.06M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M |
EPS (Basic) | -0.26 | -0.19 | 18.30 | -0.03 | -1.27 | -1.78 | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS (Diluted) | -0.26 | -0.19 | 18.30 | -0.03 | -1.27 | -1.78 | 0.01 | 0.03 | 0.03 | 0.03 | 0.02 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EBITDA | -1.72M | -5.7M | -8.01M | -1.48M | -1.24M | -1.72M | -721K | 162.95K | -793 | 494.41K | 292.58K | 42.69K | -246K | -242K | -224K | -192K | -97.75K |
EBIT | -1.73M | -5.69M | -8.04M | -1.49M | -1.25M | -1.73M | 74.14K | 162.95K | -808 | 494.41K | 292.58K | 42.69K | -246K | -242K | -224K | -192K | -97.75K |
Depreciation & Amortization | 4K | -12K | 22K | 7K | 8K | 6K | 10K | n/a | 15.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |